Richard Buka/X
Sep 23, 2025, 06:40
Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
Richard Buka, Chair of HaemSTAR, shared on X:
”Bit of pharma news here. CSL Behring have announced a colab with Dutch biotech, VarmX.
VarmX have been working on a very exciting molecule that is an antidote oral FXa inhibitors like rivaroxaban and apixaban.
What is this molecule? And why is it worth a potential $1.7bn?”
Stay updated with Hemostasis Today.
-
Aug 27, 2026, 11:08Sunisha Arora: New EBMT Recommendations Transform the Approach to HSCT in Thalassemia
-
Aug 27, 2026, 10:51Seema Dawood: A Layered Approach to Identifying Thalassemia in the Laboratory
-
Aug 27, 2026, 10:44Ed Smith: Vitalant Expands Hemophilia Center Team With New Career Opportunities
-
Aug 27, 2026, 10:43FDA Expands Hympavzi Approval to Children and Patients With Hemophilia A or B With Inhibitor
-
Aug 27, 2026, 10:28Narat Srivali: Exploring the Link Between Perioperative Corticosteroids and VTE Risk
-
Aug 27, 2026, 10:19Vincent Poher: Clinical Validation of Rapid Whole-Blood Fibrinogen Measurement
-
Aug 27, 2026, 07:49Denis Oduor: Bringing Blood Closer – Strengthening Kenya’s Response to PPH
-
Aug 27, 2026, 07:19Luis Oliverio Ambriz Garcia: ASH 2026 Guidelines – What’s New in ITP?
-
Aug 27, 2026, 06:58Priyam Bordoloi: The Biological Advantage of Two X Chromosomes